If your goal is drug discovery by checking out relevant protein structures, then you'll be lucky with useful structure information ~2/3 of the time (perhaps les

If your goal is drug discovery by checking out relevant protein structures, then you'll be lucky with useful structure information ~2/3 of the time (perhaps less, if you are depending on interactions of more than one protein). If it was possible to accelerate drug discovery by looking at computed protein structures rather than protein structures established experimentally, it has now become plausible to do so. It has crossed a tipping point. Since I'm not aware that there has been any drug discovery that has strongly depended on computational protein folding, this possible benefit remains to be seen. [I worked in a lab which was heavily involved in CASP, the protein folding competition, but I was not myself involved]